CRL - Charles River Laboratories International, Inc.

NYSE - Nasdaq Real Time Price. Currency in USD
137.10
-1.16 (-0.84%)
At close: 4:02PM EDT

137.10 0.00 (0.00%)
After hours: 4:25PM EDT

Stock chart is not supported by your current browser
Previous Close138.26
Open138.32
Bid137.28 x 1800
Ask137.33 x 1000
Day's Range137.03 - 138.53
52 Week Range103.00 - 149.07
Volume248,987
Avg. Volume374,360
Market Cap6.684B
Beta (3Y Monthly)1.17
PE Ratio (TTM)29.48
EPS (TTM)4.65
Earnings DateAug 6, 2019 - Aug 12, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est149.57
Trade prices are not sourced from all markets
  • Is Charles River Laboratories International Inc. (CRL) A Good Stock To Buy?
    Insider Monkey4 days ago

    Is Charles River Laboratories International Inc. (CRL) A Good Stock To Buy?

    Does Charles River Laboratories International Inc. (NYSE:CRL) represent a good buying opportunity at the moment? Let’s quickly check the hedge fund interest towards the company. Hedge fund firms constantly search out bright intellectuals and highly-experienced employees and throw away millions of dollars on satellite photos and other research activities, so it is no wonder why […]

  • TheStreet.com10 days ago

    Don't Jump Into Charles River Labs Just Yet

    During the Lightning Round of Mad Money Thursday night, Jim Cramer mentioned to one caller that he also likes Charles River Laboratories International Inc. In the daily bar chart of CRL, below, we can see some bearish signals. The On-Balance-Volume (OBV) line shows weakness from late April telling us that sellers of CRL have become more aggressive.

  • Markit14 days ago

    See what the IHS Markit Score report has to say about Charles River Laboratories International Inc.

    Charles River Laboratories International Inc NYSE:CRLView full report here! Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for CRL with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting CRL. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding CRL totaled $7 million. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Business Wire21 days ago

    Charles River Laboratories to Present at Jefferies and Goldman Sachs Investor Conferences

    Charles River Laboratories International, Inc. announced today that it will present at two upcoming investor conferences, including:

  • Thomson Reuters StreetEventslast month

    Edited Transcript of CRL earnings conference call or presentation 7-May-19 12:30pm GMT

    Q1 2019 Charles River Laboratories International Inc Earnings Call

  • Business Wirelast month

    Charles River Laboratories Invests in Resero Analytics™

    Access to Resero’s TurboToxicology™ will provide faster delivery of high-quality toxicology reports

  • How Do Analysts See Charles River Laboratories International, Inc. (NYSE:CRL) Performing Over The Next Year?
    Simply Wall St.last month

    How Do Analysts See Charles River Laboratories International, Inc. (NYSE:CRL) Performing Over The Next Year?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...

  • Medical Stock Pummeled On China Trade Worries — Wiping Out Earnings Beat
    Investor's Business Daily2 months ago

    Medical Stock Pummeled On China Trade Worries — Wiping Out Earnings Beat

    Charles River earnings of $1.40 a share, on an adjusted basis, on $604.6 million in sales beat first-quarter estimates Tuesday. But shares closed down on worries of a China trade war.

  • Charles River Laboratories International Inc (CRL) Q1 2019 Earnings Call Transcript
    Motley Fool2 months ago

    Charles River Laboratories International Inc (CRL) Q1 2019 Earnings Call Transcript

    CRL earnings call for the period ending .

  • Charles River Laboratories (CRL) Beats Q1 Earnings and Revenue Estimates
    Zacks2 months ago

    Charles River Laboratories (CRL) Beats Q1 Earnings and Revenue Estimates

    Charles River (CRL) delivered earnings and revenue surprises of 1.45% and 0.70%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    Charles River: 1Q Earnings Snapshot

    The Wilmington, Massachusetts-based company said it had profit of $1.11 per share. Earnings, adjusted for non-recurring costs, came to $1.40 per share. The results surpassed Wall Street expectations. The ...

  • Business Wire2 months ago

    Charles River Laboratories Announces First-Quarter 2019 Results

    – First-Quarter Revenue of $604.6 Million –

  • GlobeNewswire2 months ago

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Charles River Laboratories International, Inc. - CRL

    Pomerantz LLP is investigating claims on behalf of investors of Charles River Laboratories International, Inc. (“Charles River” or the “Company”) (NYSE: CRL).   Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. On April 30, 2019, Charles River disclosed that a “highly sophisticated, well-resourced intruder” accessed its information system in mid-March 2019, and that data belonging to “approximately 1% of Charles River’s total number of clients” was “known to have been copied”.  Following this disclosure, Charles River’s stock price fell $5.11 per share, or 3.59%, over the following two trading sessions, closing at $137.41 per share on May 1, 2019. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions.

  • Charles River Labs says its biotech, pharma clients' data was hacked
    American City Business Journals2 months ago

    Charles River Labs says its biotech, pharma clients' data was hacked

    An unidentified group of hackers recently broke into Charles River Laboratories’ information system and copied some drug developers’ data, the company disclosed Tuesday.

  • Charles River Laboratories (CRL) Q1 Earnings Preview: What's in the Cards?
    Zacks2 months ago

    Charles River Laboratories (CRL) Q1 Earnings Preview: What's in the Cards?

    Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Business Wire2 months ago

    Charles River Laboratories Completes the Acquisition of Citoxlab

    Charles River Laboratories International, Inc. (CRL) announced today that it has completed the previously announced acquisition of Citoxlab for €448 million in cash (or approximately $500 million based on current exchange rates), subject to customary closing adjustments. Citoxlab is a premier, non-clinical contract research organization (CRO), specializing in regulated safety assessment services, non-regulated discovery services, and medical device testing. With operations in Europe and North America, the acquisition of Citoxlab will further strengthen Charles River’s position as the leading, global, early-stage CRO by expanding its scientific portfolio and geographic footprint, which will enhance the Company’s ability to partner with clients across the drug discovery and development continuum.

  • Were Hedge Funds Right About Piling Into Charles River Laboratories International (CRL)?
    Insider Monkey2 months ago

    Were Hedge Funds Right About Piling Into Charles River Laboratories International (CRL)?

    Hedge funds are known to underperform the bull markets but that's not because they are terrible at stock picking. Hedge funds underperform because their net exposure in only 40-70% and they charge exorbitant fees. No one knows what the future holds and how market participants will react to the bountiful news that floods in each […]

  • Here's How P/E Ratios Can Help Us Understand Charles River Laboratories International, Inc. (NYSE:CRL)
    Simply Wall St.2 months ago

    Here's How P/E Ratios Can Help Us Understand Charles River Laboratories International, Inc. (NYSE:CRL)

    This article is written for those who want to get better at using price to earnings ratios (P/E ratios). We'll look at Charles River Laboratories International, Inc.'s (NYSE:CRL) P/E ratio and reflect on what it tells us about the...

  • Top Ranked Growth Stocks to Buy for April 12th
    Zacks2 months ago

    Top Ranked Growth Stocks to Buy for April 12th

    Top Ranked Growth Stocks to Buy for April 12th

  • Teladoc's Partnership to Form Pediatric Telehealth Platform
    Zacks2 months ago

    Teladoc's Partnership to Form Pediatric Telehealth Platform

    Teladoc (TDOC) teams up with Cincinnati Children's Hospital Medical Center to launch consumer pediatric telehealth platform.

  • Business Wire2 months ago

    Charles River Laboratories Schedules First-Quarter 2019 Earnings Release and Conference Call

    Charles River Laboratories International, Inc. (CRL) will release first-quarter 2019 financial results on Tuesday, May 7th, before the market opens. Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts.